Revision as of 10:54, 17 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,074 edits Saving copy of the {{drugbox}} taken from revid 456518685 of page Edrecolomab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 20:33, 1 December 2023 edit Buidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,147 editsm Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot |
Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 447617838 |
|
| verifiedrevid = 461092781 |
|
| image = |
|
| image = |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = o |
|
| source = o |
|
| target = ] (17-1A) |
|
| target = ] (17-1A) |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
⚫ |
| tradename = Panorex |
⚫ |
<!--Clinical data--> |
|
⚫ |
| tradename = |
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
|
|
| bioavailability = |
⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
| metabolism = |
|
|
⚫ |
| excretion = |
⚫ |
| elimination_half-life = |
|
|
⚫ |
<!-- Identifiers --> |
⚫ |
| excretion = |
|
|
|
|
⚫ |
<!--Identifiers--> |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = <!-- blanked - oldvalue: 156586-89-9 --> |
|
| CAS_number = 156586-89-9 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 0KYI9U9FSJ |
|
| ATC_prefix = L01 |
|
| ATC_prefix = L01 |
|
| ATC_suffix = XC01 |
|
| ATC_suffix = FX01 |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = DB13375 |
|
⚫ |
<!-- Chemical data --> |
|
⚫ |
| chemical_formula = |
|
⚫ |
| molecular_weight = |
|
⚫ |
}} |
|
|
|
|
|
|
'''Edrecolomab''' (MAb17-1A, trade name '''Panorex''') is a mouse-derived ] targeting the cell-surface ] ] (17-1A), which is expressed on ] and on various ]s. |
⚫ |
<!--Chemical data--> |
|
⚫ |
| chemical_formula = |
|
|
|
|
|
|
|
Preliminary studies had shown promise of a possible use in patients with stage III ] (with ] to the ]).<ref name="Lancet1994">{{cite journal | vauthors = Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R | display-authors = 6 | title = Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group | journal = Lancet | volume = 343 | issue = 8907 | pages = 1177–83 | date = May 1994 | pmid = 7909866 | doi = 10.1016/s0140-6736(94)92398-1 | s2cid = 45574458 }}</ref><ref name="Proc2002">{{cite journal | vauthors = Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S | display-authors = 6 | title = Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study | journal = Lancet | volume = 360 | issue = 9334 | pages = 671–7 | date = August 2002 | pmid = 12241873 | doi = 10.1016/S0140-6736(02)09836-7 | s2cid = 42391189 }}</ref> No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.<ref name="stageII">{{cite journal | vauthors = Colacchio TA, Niedzwiecki D, Compton C, Warren R, Benson AI, Goldberg R, Kerr D, Fields A, Hollis D, Mayer R | title = Phase III trial of adjuvant immunotherapy with MOAb 17–1A following resection for stage II adenocarcinoma of the colon (CALGB 9581) | journal = Journal of Clinical Oncology | date = July 2004 | volume = 22 | issue = 14_suppl | pages = 3522 | doi = 10.1200/jco.2004.22.90140.3522 }}</ref> |
⚫ |
| molecular_weight = |
|
|
|
|
⚫ |
}} |
|
|
|
Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer. |
|
|
|
|
|
== References == |
|
|
{{reflist|2}} |
|
|
|
|
|
{{Extracellular chemotherapeutic agents}} |
|
|
{{Monoclonals for tumors}} |
|
|
|
|
|
] |
|
|
] |
|
|
{{monoclonal-antibody-stub}} |
|
|
{{antineoplastic-drug-stub}} |